

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:	d'Azzo	Group Art Unit:	Not assigned
Appl. No.:	To be Assigned; Divisional Of U.S. Appln. No. 09/966,893	Examiner:	Not assigned
Filed:	Filed Concurrently Herewith		
For:	Targeting Proteins for Cells Expressing Mannose Receptors Via Expression in Insect Cells		

Mail Stop Patent Application
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT
CITATION UNDER 37 CFR § 1.97**

Sir:

Attached is a list of documents on form PTO-1449. It is requested that the Examiner consider these documents and officially make them of record in accordance with the provisions of 37 CFR § 1.97 and Section 609 of the MPEP. By submitting the listed documents, Applicant in no way makes any admission as to the prior art status of the listed documents, but is instead submitting the listed documents for the sake of full disclosure.

All listed items were cited by the Applicant or Examiner in parent Application No. 09,966,893, filed September 28, 2001. Since the benefit of this prior application was claimed under 35 USC 120, no copies need to be furnished in accordance with 37 CFR 1.98(d); however, copies will be furnished upon request. No fees for consideration of this statement beyond those provided for in documents accompanying this paper are believed to be necessary. However, in the event that additional fees are necessary to allow consideration of this paper, such fees required therefore (including fees for net addition of claims) are hereby authorized to be charged to Deposit Account No. 501968.

Respectfully submitted,



J. Scott Elmer
Attorney/Agent for Application
Registration No. 36,129

Customer No. 28258

St. Jude Children's Research Hospital

332 N. Lauderdale St.

Mailstop 742

Memphis, TN 38105


Tel: (901) 495-2342

Fax: (901) 495-3148

"Express Mail": EL 402017438 US

Date Mailed: December 11, 2003

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Commissioner for Patents, Mail Stop Patent Application, PO Box 1450 Alexandria, VA 22313-1450


Regina D. McKinney

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known		
				Application Number	Not yet assigned	
				Filing Date		
				First Named Inventor	d'Azzo	
				Art Unit	1652	
Examiner Name	Christian L. Fronda					
Sheet	1	of	5	Attorney Docket Number	SJ-01-0020A	

US PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication or issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Name of Inventor(s)
		Number-Kind Code ² (if known)			
	AA1	US-5,179,023	01-12-1993	Research Corp. Tech. Inc.	Calhoun et al.
	AB1	US-5,658,567	09-19-1997	Research Corp. Tech. Inc.	Calhoun et. al.
	AC1	US-5,762,939	06-09-1998	MG-PMC, LLC	Smith et. al.
	AD1	US-6,183,987	02-06-2001	Stichting Institut voor Dierhouderij en Diergeneeskunde	van de Weil et. al.
	AE1	US-6,225,060	05-01-2001	Onyx Pharmaceuticals, Inc	Clark et. al.
	AF	US-			
	AG	US-			
	AH	US-			
	AI	US-			
	AJ	US-			
	AK	US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Page, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³	Number ⁴ - Kind Code ⁵ (if known)			
	AL	WO	00/39150	07/06/2000	Sharp, J.	
	AM					
	AN					
	AO					
	AP					

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO : Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/966893
				Filing Date	September 28, 2001
				First Named Inventor	d'Azzo
				Art Unit	1646
				Examiner Name	To be assigned
Sheet	2	of	5	Attorney Docket Number SJ-01-0020	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher city and/or country where published	T ²	
	AR1	AEED, P.A. <i>et al</i> , "Glycosylation of recombinant prorenin in insect cells: the insect cell line Sf9 does not express the mannose 6-phosphate recognition signal", <i>Biochemistry</i> 33(29):8793-97 (1994)		
	AS1	AOKI, M. <i>et al</i> , "Improvement of neurological symptoms by enzyme replacement therapy for Gaucher Disease Type IIb", <i>Eur. J. Pediatr.</i> , 160(1): 63-64 (2001)		
	AT1	BERG, T. <i>et al</i> , "Purification and characterization of recombinant human lysosomal alpha-mannosidase", <i>Mol Genet Metab.</i> , 73(1):18-29 (2001)		
	AU1	BIJSTERBOSCH, M.K. <i>et al</i> , "Quantitative analysis of the targeting of mannose-terminal glucocerebrosida; Prodominant uptake by liver endothelial cells", <i>Eur. J. Biochem.</i> , 237:344-349 (1996)		
	AV1	BONTEN, E.J. <i>et al</i> , "Lysosomal Protective Protein/Cathepsin A" <i>Journal of Biological Chemistry</i> 270(44): 26441-26445 (1995)		
	AW1	BONTEN, E.J. <i>et al</i> , "Catalytic Activation in Insect Cells is Controlled by the Protective Protein/Cathepsin A", <i>Journal of Biological Chemistry</i> 275(48): 37657-37663 (2000)		
	AX1	BONTEN, E.J. <i>et al</i> , "Correction of lysosomal PPCA and neuraminidase in mouse deficient macrophages after uptake of recombinant baculovirus-expressed proteins", <i>Amer. J. Hum. Gen. Suppl.</i> 69(4):Abst 1759 (2001)		
	AY1	BOOSE, J.A. <i>et al</i> , "Synthesis of a human lysosomal enzyme, beta-hexosaminidase B, using the baculovirus expression system", <i>Protein Expr. Purif.</i> 1(2):111-20 (1990)		
	AZ1	BROMME, D. <i>et al</i> , "High level expression and crystallization of recombinant human cathepsin S", <i>Protein Sci.</i> , 5(4):789-91 (1996)		
	AR2	CALHOUN, D.H. <i>et al</i> , "Fabry disease: Isolation of a cDNA clone encoding human α -galactosidase A", <i>PNAS</i> 82:7364-68 (1985)		
	AS2	CHEN, Y. <i>et al</i> , "Purification and Characterization of Human α -Galactosidase A Expressed in Insect Cells Using a Baculovirus Vector", <i>Protein Expression and Purification</i> 20:228-236 (2000)		
	AT2	COPPOLA, G. <i>et al</i> , "Characterization of glycosylated and catalytically active recombinant human alpha-Galactosidase A using a baculovirus vector", <i>Gene</i> 144(2):197-203 (1994)		
	AU2	D'AZZO, A., "Biochemical properties of PPCA and neuraminidase", Presentation at Strategies for Therapy of MPS and Related Diseases and 16 th Annual MPS Conference held on June 22, 2001 at UCLA		
	AV2	DAVIDSON, D.J. <i>et al</i> , "Oligosaccharide Processing in the Expression of Human Plasminogen cDNA by Lepidopteran Insect (<i>Spodoptera frugiperda</i>) Cells", <i>Biochemistry</i> 29(23): 5584-5590 (1990)		
	AW2	DAVIDSON, D.J. <i>et al</i> , "Asparagine-Linked Oligosaccharide Processing in Lepidopteran Insect Cells. Temporal Dependence of the Nature of the Oligosaccharides Assembled on Asparagine-289 of Recombinant Human Plasminogen Produced in Baculovirus Vector Infected <i>Spodoptera frugiperda</i> (IPBL-SF-21AE) Cells", <i>Biochemistry</i> 30(25): 6167-6174 (1991)		
	AX2	DAVIS, T.R. <i>et al</i> , "Intrinsic Glycosylation Potentials of Insect Cell Cultures and Insect Larvae", <i>In Vitro Cell. Dev.Biol.</i> 31:659-663 (1995)		
	AY2	DESNICK, R.J. "Enzyme replacement and beyond", <i>J Inheret Metab Dis.</i> 24(2):251-65 (2001)		
	AZ2	ENG, C.M. <i>et al</i> , "A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies", <i>Am. J. Hum. Genet.</i> , 68(3): 711-22 (2001)		
	AR3	HAHN, C.N. <i>et al</i> , "Correction of murine galactosialidosis by bone marrow-derived macrophages overexpressing human protective protein/cathepsin A under control of the colony-stimulating factor-1 receptor promoter", <i>PNAS</i> 95:14880-85 (1998)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/966893
				Filing Date	September 28, 2001
				First Named Inventor	D'Azzo
				Art Unit	1646
				Examiner Name	To be assigned
Sheet	3	of	5	Attorney Docket Number SJ-01-0020	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher city and/or country where published	T ²
	AS3	HOLLISTER, J.R. <i>et al</i> , "Engineering lepidopteran insect for sialoglycoprotein production by genetic transformation with mammalian β 1,4-galactosyltransferase and α 2,6-sialyltransferase genes", <i>Glycobiology</i> 11: 1-9 (2001)	
	AT3	HSU, T. <i>et al</i> , "Differential N-Glycan Patterns of Secreted and Intracellular IgG Produced in <i>Trichoplusia ni</i> cells", <i>Journal of Biological Chemistry</i> 272(14): 9062-9070 (1997)	
	AU3	IDA, H. <i>et al</i> , "Effects of enzyme replacement therapy in thirteen Japanese pediatric patients with Gaucher Disease", <i>Eur. J. Pediatr.</i> 106(1): 21-5 (2001)	
	AV3	IOANNOU, Y.A. <i>et al</i> , "Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase a replacement in enzyme-deficient mice", <i>Am. J. Hum. Genet.</i> 68(1): 14-25 (2001)	
	AW3	JARVIS, D.L. <i>et al</i> , "Biochemical Analysis of the N-Glycosylation Pathway in Baculovirus-Infected Lepidopteran Insect Cells", <i>Virology</i> 212: 500-511 (1995)	
	AX3	JARVIS, D.L. <i>et al</i> , "Modifying the insect cell N-glycosylation pathway with immediate early baculovirus Expression vectors", <i>Nature Biotechnology</i> 14:1288-1292 (1996)	
	AY3	JARVIS, D.L. <i>et al</i> , "Engineering N-glycosylation pathways in the baculovirus-insect cell system", <i>Current Opinion In Biotechnology</i> 9: 528-533 (1998)	
	AZ3	JARVIS, D.L. <i>et al</i> , "Mutational Analysis of the N-Linked Glycans on <i>Autographa californica</i> Nucleopolyhedrovirus gp64", <i>Journal of Virology</i> 72(12): 9459-9469 (1998)	
	AR4	JARVIS, D.L. <i>et al</i> , "Novel baculovirus expression vectors that provide sialylation of recombinant glycoproteins in lepidopteran insect cells", <i>J. Virol.</i> 75(13): 6223-27 (2001)	
	AS4	KAKKIS, E.D. <i>et al</i> , "Enzyme-replacement therapy in mucopolysaccharidosis I", <i>N. Engl. J. Med.</i> 344(3): 182-188 (2001)	
	AT4	KAULI, R. <i>et al</i> , "Delayed Growth in Puberty in Patients with Gaucher Disease Type 1: Natural History And Effects of Splenectomy and/or Enzyme Replacement Therapy", <i>Isr. Med. Assoc. J.</i> 2(2): 158-63 (2000)	
	AU4	KAWAR, Z. <i>et al</i> , "Insect cells encode a class II α -Mannosidase with Unique properties", <i>J. Biol. Chem.</i> 276(19): 16335-40 (2001)	
	AV4	LEW, D.B. <i>et al</i> , "Mitogenic effect of lysosomal hydrolases on bovine tracheal myocytes in culture", <i>J. Clin. Invest.</i> , 99: 1969-1975 (1991)	
	AW4	LEW, D.B. <i>et al</i> , "A mannose receptor mediates mannosyl-rich glycoprotein-induced mitogenesis in bovine airway smooth muscle cells", <i>J. Clin. Invest.</i> 94:1855-1863 (1994)	
	AX4	LICARI, P.J. <i>et al</i> , "Insect Cell Hosts for Baculovirus Expression Vectors Contain Endogenous Exoglycosidase Activity", <i>Biotechnol. Prog.</i> 9:146-152 (1993)	
	AY4	LIN, L. <i>et al</i> , "Production and characterization of recombinant human CLN2 protein for enzyme-replacement therapy in late infantile neuronal ceroid lipofuscinosis", <i>Biochem J.</i> 357: 49-55 (2001)	
	AZ4	LIU, Z. <i>et al</i> , "TNF- α and IL-1 α induce mannose receptors and apoptosis in glomerular mesangial but not endothelial cells", <i>Am. J. Physiol.</i> 270: C1595-1601 (1996)	
	AR5	LUTZ, D.A. <i>et al</i> , "Natural, high-mannose glycoproteins inhibit ROS binding and ingestion by RPE cell cultures", <i>Exp. Eye Res.</i> 61: 487-493 (1995)	
	AS5	MAGNUSSON, S. <i>et al</i> , "Endocytosis of ricin by rat liver cells <i>in vivo</i> and <i>in vitro</i> is mainly mediated by mannose receptors on sinusoidal endothelial cells", <i>Biochem J.</i> 291: 749-755 (1993)	
	AT5	MARCHAL, I. <i>et al</i> , "Glycoproteins from insect cells: Sialylated or Not?", <i>Biol. Chem.</i> 382(2): 151-159 (2001)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/966893
				Filing Date	September 28, 2001
				First Named Inventor	d'Azzo
				Art Unit	1646
				Examiner Name	To be assigned
Sheet	4	of	5	Attorney Docket Number SJ-01-0020	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher city and/or country where published	T ²	
	AU5	MARTIN, B.M. <i>et al</i> , "Glycosylation and processing of high levels of active human glucocerebrosidase in Invertebrate cells using a baculovirus expression vector", <i>DNA</i> 7(2): 99-106 (1988)		
	AV5	OGONAH, O.W. <i>et al</i> , "Isolation and Characterization of an Insect Cell Line Able to Perform Complex N-Linked Glycosylation on Recombinant Proteins" <i>Biotechnology</i> 14:197-202 (1996)		
	AW5	PASTORES, G.M. <i>et al</i> , "Enzyme-replacement therapy for Anderson-Fabry disease", <i>Lancet</i> , 358(9282): 601-603 (Aug. 25 2001)		
	AX5	REIS eSOUSA, C. <i>et al</i> , "Phagocytosis of antigens by langerhans cells in vitro", <i>J. Exp. Med.</i> 178: 509-519 (1993)		
	AY5	ROULIEUX-BONNIN, F. <i>et al</i> , "Transcriptional expression of mannose receptor gene during differentiation of human macrophages", <i>Biochem. Biophys. Res. Comm.</i> 217: 106-112 (1995)		
	AZ5	RUDENKO, G. <i>et al</i> , "Three-dimensional structure of the human protective protein; structure of the precursor Form suggests a complex activation mechanism", <i>Structure</i> 3(11): 1249-1259 (1995)		
	AR6	RUDENKO, G. <i>et al</i> , "The atomic model of the human protective protein/cathepsin A suggests a Structural basis for galactosialidosis", <i>PNAS</i> 95: 621-625 (1998)		
	AS6	SALLUSTO, F. <i>et al</i> , "Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartments: Downregulation by cytokines and bacterial products", <i>J. Exp. Med.</i> 182: 389-400 (1995)		
	AT6	SCHIFFMANN, R. <i>et al</i> , "Enzyme replacement therapy in Fabry Disease: a randomized controlled trial", <i>JAMA</i> , 285(21): 2743-2749 (2001)		
	AU6	SEO, N. <i>et al</i> , "Mammalian glycosyltransferase expression allows sialoglycoprotein production by baculovirus-infected insect cells", <i>Protein Expr. Purif.</i> 22(2):234-41 (2001)		
	AV6	SHEPARD, V.L. <i>et al</i> , "Isolation and characterization of a mannose receptor from human pigment epithelium" <i>Invest. Ophthalmol. Vis. Sci.</i> 32(6): 1779-1784 (1991)		
	AW6	SLY, W.S. <i>et al</i> , "Active site mutant transgene confers tolerance to human beta - glucuronidase without affecting the phenotype of MPS VII mice", <i>PNAS</i> 98(5): 2205-10 (Feb 27, 2001)		
	AX6	STAHL, P.D. <i>et al</i> , "The mannose receptor is a pattern recognition receptor involved in host defense", <i>Current Opinion in Immunology</i> 10: 50-55 (1998)		
	AY6	STEED, P.M. <i>et al</i> , "Characterization of recombinant human cathepsin B expressed at high levels in baculovirus", <i>Protein Science</i> 7(9): 2033-37 (1998)		
	AZ6	STEHLER, S.E. <i>et al</i> , "A Soluble Mannose Receptor Immunoconjugate Enhances Phagocytosis of <i>Pneumocystis Carinii</i> by Human Polymorphonuclear Leukocytes <i>In Vitro</i> ", <i>Scandinavian Journal of Immunology</i> 52: 131-137 (2000)		
	AR7	TAYLOR, M.E., "Structure and Function of the Macrophage Mannose Receptor", <i>Results and Problems in Cell Differentiation</i> 33:105-121 (2001)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/966893
				Filing Date	September 28, 2001
				First Named Inventor	D'Azzo
				Art Unit	1646
				Examiner Name	To be assigned
				Attorney Docket Number	SJ-01-0020
Sheet	5	of	5		

[illegible]

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231**